Shares of the clinical-stage biotech Celldex Therapeutics (NASDAQ: CLDX) fell by 14.7% in October, according to S&P Global Market Intelligence. The good news — if you can call it that — is that Celldex’s shares appear to have fallen simply because investors are tired of waiting for a major clinical update from the company’s ongoing mid-stage trial assessing the antibody drug conjugate (ADC) glembatumumab vedotin, or glemba, in patients with triple negative breast cancer (TNBC).